JP Morgan Chase’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

JP Morgan Chase’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45	Closed	-$29	–	7848
2024 Q4	$29	Buy	45 +14	+45%	+$6	﹤0.01%	7224
2024 Q3	$12	Buy	+31	New	+$28	﹤0.01%	7284
2023 Q4	–	Sell	-100,557	Closed	-$835K	–	7946
2023 Q3	$835K	Hold	100,557	–	–	﹤0.01%	4176
2023 Q2	$1.04M	Sell	100,557 -100,000	-50%	-$1.02M	﹤0.01%	4038
2023 Q1	$2.03M	Sell	200,557 -234,433	-54%	-$2.37M	﹤0.01%	3528
2022 Q4	$4.33M	Buy	434,990 +334,433	+333%	+$3.3M	﹤0.01%	2950
2022 Q3	$980K	Hold	100,557	–	–	﹤0.01%	4024
2022 Q2	$976K	Hold	100,557	–	–	﹤0.01%	4113
2022 Q1	$975K	Buy	100,557 +92,320	+1,121%	+$895K	﹤0.01%	4292
2021 Q4	$80K	Hold	8,237	–	–	﹤0.01%	5773
2021 Q3	$80K	Buy	+8,237	New	+$80.3K	﹤0.01%	5678

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

JP Morgan Chase's NKGN Position: Q1 2025 in Review

JP Morgan Chase sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 45 shares — an estimated $29 sold.

JP Morgan Chase first reported a position in NKGN in Q3 2021 and held it in 11 quarters. The position peaked at $4.33M in Q4 2022. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

JP Morgan Chase reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
JP Morgan Chase sold 45 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $29.
JP Morgan Chase first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 11 quarters.
JP Morgan Chase's NKGen Biotech, Inc. Common Stock position peaked at $4.33M in Q4 2022.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.